The spate of recent carve-outs from Boston Scientific has private equity and venture capital investors hungry for similar deals across the industry. But device companies don't seem to be serving much up.
By Tom Salemi
Boston Scientific Corp. has spent the last year carving itself up like a Thanksgiving turkey. The company—still working through...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Entrepreneurialism is in the blood of Israel’s medtech innovators, but in a changing medtech world, the local ecosystem must address funding gaps and manufacturing and infrastructure needs. So says Ruti Alon, experienced Israeli medtech leader, investor and co-chair of the Biomed Israel conference.
During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.
Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.
